samedan logo
 
 
 
spacer
home > ebr > Summer 2020
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2020
   
Text
PDF
bullet
Features
Surfacing Missed Opportunities

David Gwyn at Amplexor

There are five areas in which richer, more holistic product information could shine a light into the life science industry’s blind spots and help transform business outcomes
 
view
download pdf
Base Editing and Its Application to Cell and Gene Therapy

Dr Ceri Wiggins at Horizon Discovery

CRISPR-Cas gene editing has been a force to be reckoned with in gene engineering for years, and it doesn’t seem likely this is going to change anytime soon


 
view
download pdf
Nova Biomedical FLEX®2

With over 1,300 employees and manufacturing facilities in Waltham and Billerica, Massachusetts, and Taipei, Taiwan, Nova Biomedical is one of the 25 largest in vitro diagnostic companies in the world and the largest privately owned in vitro diagnostic company in the US
 
view
download pdf
bullet
Analytical Methods
Risk Management for Analytical Method Development

Madalena R Testas, Daniela B Santos, and José C Menezes at 4Tune Engineering

In the biopharmaceutical industry, analytical methods are among the most critical elements for process monitoring and product release
 
view
download pdf
Beyond Big Data

Joern Klinger at biotx.ai

We can’t always rely on Big Data to be available; therefore, it’s worth suggesting ways of still effectively applying machine learning when that’s the case
 
view
download pdf
Genotoxic Impurities in Drug Products: Review of Nitrosamine Assays

Elodie Barrau, Emmanuel Desmartin, Valentina Paschetta, Davide Tartaglione, Mònica Coll Furest, and Ana Novak at Eurofins

In the past couple of years, the prevalence of nitrosamines in drug substances has made them a hot topic of conversation in the medical industry
 
view
download pdf
bullet
R&D on COVID-19
The Quest for a Cure

David Wilson at Avacta

It's of little doubt that there is a great need for the development of rapid diagnostic tests to tackle the COVID-19 pandemic
 
view
download pdf
Leveraging Health Data to Support Patient Care

Gilles Paubert at Cegedim Health Data

There are some key areas where current real-world data can add immediate value to patients, the healthcare system, and our economies



 
view
download pdf
Would Greater Diversity and Inclusion Improve Innovation?


Stephen Frost at Frost Included

The pharma industry is responsible for great strides in world health, yet it’s undeniable that there are still many more goals to accomplish, and a lack of diversity may be holding it back

 
view
download pdf
A Conversation with an Expert in Drug Development

As the world grapples with the impact of the COVID-19 pandemic, the life science industry and regulators are racing to find an effective treatment. We spoke with Colin Orford, Senior Vice President of Drug Development services at ICON plc about the direction that this work is taking
 
view
download pdf
bullet
Improving Drug Discovery Models
The Promise of Drug Discovery

The past few decades have seen large strides in the medical industry, but there are still many patients suffering with unmet medical needs that could benefit from further innovation, especially in drug discovery. EBR spoke to Dr Craig Fox, CSO at C4X Discovery, to ask about his thoughts on the subject

 
view
download pdf
Microphysiological Systems Emerging as Powerful Tools for Drug Discovery

Dr Audrey Dubourg at CN Bio

A new class of in vitro model is expected to assist drug discovery by providing robust physiologically relevant data at critical stages of R&D
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

SGD Pharma takes lead in sustainability, awarded Platinum EcoVadis rating for the first time

Puteaux Cedex, FRANCE – XX January: SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry, has been awarded a ‘platinum’ rating by EcoVadis, positioning it in the top 1% of all companies rated worldwide. This highlights SGD Pharma’s commitment to sustainable practices and corporate social responsibility (CSR). EcoVadis is the internationally recognized sustainability ratings provider, evaluating over 75,000 companies globally across a range of different industries.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

Industry Events

Bio Integrates 2021

20 May 2021, VIRTUAL CONFERENCE

Following the continued success of last year’s inaugural digital event, Life Science Integrates is delighted to announce the 3rd Bio Integrates conference. Addressing the needs of innovative companies developing the therapies of tomorrow, this one-day conference provides a unique forum to discuss the major challenges impacting the sector.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement